Recombinant Hepatitis B Vaccine（Hansenula polymorpha）(Berna Biotech Korea)

重组乙型肝炎疫苗（汉逊酵母）（科伯纳）

Report date: 2026/03/31 20:00:21

Base Information

Drug NameRecombinant Hepatitis B Vaccine（Hansenula polymorpha）(Berna Biotech Korea)
Drug Alias Name重组乙型肝炎疫苗（Crucell）Hepatitis B vaccine recombinant (Crucell)Hepavax-Gene TFHepavax-GeneSupervax +[8] 
ClassificationVaccines > National Immunization Program > Immunization program vaccine(Class I)Vaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsHepatitis BHIV Infections
Global Approved IndicationsHepatitis B
Approved Indications in ChinaHepatitis B
Original Approved Country/TerritorySouth Korea
Original Approved Date1996/01/01
Country/TerritoryThailandSouth KoreaMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesCrucell Holland BvDynavax Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesBerna Biotech Korea Corp
Inactive CompaniesChiang Mai UniversityYuanda Weixin Life Science (Nanjing) Co Ltd
Active IndicationsHepatitis B
Inactive IndicationsHIV Infections

Other Information

ATC CodeJ07BC01
Related LinksN/A